dataset
posted on 2023-03-31, 00:20 authored by Andriy Marusyk, Doris P. Tabassum, Michalina Janiszewska, Andrew E. Place, Anne Trinh, Andrii I. Rozhok, Saumyadipta Pyne, Jennifer L. Guerriero, Shaokun Shu, Muhammad Ekram, Alexander Ishkin, Daniel P. Cahill, Yuri Nikolsky, Timothy A. Chan, Mothaffar F. Rimawi, Susan Hilsenbeck, Rachel Schiff, Kent C. Osborne, Antony Letai, Kornelia Polyak Associations between molecular features and clinical outcome. Patient outcome and changes in pSTAT3+, SMA+, Ki67+ cells and distance between Ki67+&SMA+ cells are indicated. Initial values from Day 0 where possible, otherwise Day 1. For continuous data, increase or decrease of at least 5% of initial value used as a threshold. Changes computed as Time0 - mean (Time 2,4,6 weeks). Outcome is percentage shrinkage of tumor at week 6.
Funding
DBT
Shula fund
NIH
Breast Cancer Research Foundation
History
ARTICLE ABSTRACT
Using a three-dimensional coculture model, we identified significant subtype-specific changes in gene expression, metabolic, and therapeutic sensitivity profiles of breast cancer cells in contact with cancer-associated fibroblasts (CAF). CAF-induced gene expression signatures predicted clinical outcome and immune-related differences in the microenvironment. We found that fibroblasts strongly protect carcinoma cells from lapatinib, attributable to its reduced accumulation in carcinoma cells and an elevated apoptotic threshold. Fibroblasts from normal breast tissues and stromal cultures of brain metastases of breast cancer had similar effects as CAFs. Using synthetic lethality approaches, we identified molecular pathways whose inhibition sensitizes HER2+ breast cancer cells to lapatinib both in vitro and in vivo, including JAK2/STAT3 and hyaluronic acid. Neoadjuvant lapatinib therapy in HER2+ breast tumors lead to a significant increase of phospho-STAT3+ cancer cells and a decrease in the spatial proximity of proliferating (Ki67+) cells to CAFs impacting therapeutic responses. Our studies identify CAF-induced physiologically and clinically relevant changes in cancer cells and offer novel approaches for overcoming microenvironment-mediated therapeutic resistance. Cancer Res; 76(22); 6495–506. ©2016 AACR.
